{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:08:12Z","timestamp":1784592492867,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#U25A20117"],"award-info":[{"award-number":["#U25A20117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02144-4","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:12:54Z","timestamp":1779693174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Xingzhe","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihua","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2144_CR1","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonz\u00e1lez-Mart\u00edn A, Moore KN, Colombo N, Ray-Coquard I, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31:1148\u201359.","journal-title":"Ann Oncol"},{"key":"2144_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44178-023-00068-3","volume":"3","author":"L Li","year":"2024","unstructured":"Li L, Lang J. Recent advances in the treatment for gynecologic oncology. Holist Integr Oncol. 2024;3:1.","journal-title":"Holist Integr Oncol"},{"key":"2144_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2025.03.018","volume":"195","author":"UA Matulonis","year":"2025","unstructured":"Matulonis UA, Herrstedt J, Oza A, Mahner S, Redondo A, Berton D, et al. ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety. Gynecol Oncol. 2025;195:192\u20139.","journal-title":"Gynecol Oncol"},{"key":"2144_CR4","doi-asserted-by":"publisher","first-page":"115584","DOI":"10.1016\/j.ejca.2025.115584","volume":"225","author":"JA Ledermann","year":"2025","unstructured":"Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. Eur J Cancer. 2025;225:115584.","journal-title":"Eur J Cancer"},{"key":"2144_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","volume":"119","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018;119:1075\u201385.","journal-title":"Br J Cancer"},{"key":"2144_CR6","doi-asserted-by":"publisher","first-page":"2351003","DOI":"10.1080\/20523211.2024.2351003","volume":"17","author":"M Shahzad","year":"2024","unstructured":"Shahzad M, Naci H, Esselen KM, Dottino JA, Wagner AK. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway. J Pharm Policy Pract. 2024;17:2351003.","journal-title":"J Pharm Policy Pract"},{"key":"2144_CR7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1136\/ijgc-2023-004478","volume":"33","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Coleman RL, Mirza MR. Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency. Int J Gynecol Cancer. 2023;33:1008\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"2144_CR8","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-21-3023","volume":"28","author":"Q Gao","year":"2022","unstructured":"Gao Q, Zhu J, Zhao W, Huang Y, An R, Zheng H, et al. Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA). Clin Cancer Res. 2022;28:2278\u201385.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2144_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/ajco.13753","volume":"18","author":"J Liu","year":"2022","unstructured":"Liu J, Yin R, Wu L, Zhu J, Lou G, Wu X, Zhou Q, Gao Y, Kong B, Lu X, et al. Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial. Asia Pac J Clin Oncol. 2022;18(6):714\u201322.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2144_CR10","doi-asserted-by":"publisher","first-page":"e15025","DOI":"10.1200\/JCO.2022.40.16_suppl.e15025","volume":"40","author":"C-F Li","year":"2022","unstructured":"Li C-F, Chen S-J, Tan K, Tse K-P, Wang W-F. Performance and clinical utility of homologous recombination deficiency (HRD) determined by genome-wide loss of heterozygosity (LOH). J Clin Oncol. 2022;40:e15025\u2013e.","journal-title":"J Clin Oncol"},{"key":"2144_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12916-024-03409-9","volume":"22","author":"H Li","year":"2024","unstructured":"Li H, Peng Z, Zhu J, Zhao W, Huang Y, An R, et al. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer. BMC Med. 2024;22:199.","journal-title":"BMC Med"},{"key":"2144_CR12","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.22.01934","volume":"40","author":"WP Tew","year":"2022","unstructured":"Tew WP, Lacchetti C, Kohn EC. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022;40:3878\u201381.","journal-title":"J Clin Oncol"},{"issue":"10106","key":"2144_CR13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u201361.","journal-title":"Lancet"},{"key":"2144_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"22","key":"2144_CR15","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"key":"2144_CR16","doi-asserted-by":"publisher","first-page":"102629","DOI":"10.1016\/j.eclinm.2024.102629","volume":"72","author":"X Wu","year":"2024","unstructured":"Wu X, Zhu J, Yin R, Yang J, Liu J, Wang J, et al. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial. EClinicalMedicine. 2024;72:102629.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2144_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620\u201331.","journal-title":"Lancet Oncol"},{"key":"2144_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2025.04.580","volume":"197","author":"A Poveda","year":"2025","unstructured":"Poveda A, Lheureux S, Colombo N, Cibula D, Elstrand M, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, Gonz\u00e1lez-Mart\u00edn A, et al. Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and\/or BRCA2 mutation: Final overall survival results from the OPINION trial. Gynecol Oncol. 2025;197:74\u201382.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2144_CR19","doi-asserted-by":"publisher","first-page":"100033","DOI":"10.1016\/j.esmoop.2020.100033","volume":"6","author":"Z Ma","year":"2021","unstructured":"Ma Z, Sun XM, Lu WC, Zhao ZX, Xu ZM, Lyu JY, Zhao P, Liu LH. Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome\/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database. ESMO Open. 2021;6(1):100033.","journal-title":"ESMO Open"},{"issue":"3","key":"2144_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","volume":"161","author":"R Nitecki","year":"2021","unstructured":"Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol. 2021;161(3):653\u20139.","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02144-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02144-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02144-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:38:56Z","timestamp":1784590736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02144-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2144"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02144-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial protocol and its amendments were approved by the Chinese national regulatory authority and ethics committees at each participating center [(2018)-(3)-No.4 for the leading site]. The study (NCT03534453) complied with the Declaration of Helsinki and Good Clinical Practice guidelines. Informed written consent was obtained from all study participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NCT03534453.","order":4,"name":"Ethics","label":"Clinical trial registration number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"243"}}